- |||||||||| sodium iodide I 131 / Generic mfg.
Review, Journal: Imaging-Guided Targeted Radionuclide Tumor Therapy: From Concept to Clinical Translation. (Pubmed Central) - Oct 19, 2022
Since the first introduction of sodium iodide I-131 for use with thyroid patients almost 80 years ago, more than 50 radiopharmaceuticals have reached the markets for a wide range of diseases, especially cancers...This strategy leads to significantly enhanced therapeutic efficacy, improved patient outcomes, and manageable adverse events. In this review, we provide an overview of imaging-guided targeted radionuclide therapy for different tumors such as advanced prostate cancer and neuroendocrine tumors, with a focus on development of new radioligands and their preclinical and clinical results, and further discuss about challenges and future perspectives.
- |||||||||| Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment open, Combination therapy, Metastases: ALTER-T002: Anlotinib or Penpulimab in Combination With RAI for DTC (clinicaltrials.gov) - Jan 28, 2022
P2, N=42, Recruiting,
In this review, we provide an overview of imaging-guided targeted radionuclide therapy for different tumors such as advanced prostate cancer and neuroendocrine tumors, with a focus on development of new radioligands and their preclinical and clinical results, and further discuss about challenges and future perspectives. Not yet recruiting --> Recruiting
|
